Enlivex Therapeutics Ltd.


Enlivex Therapeutics Ltd. Website Screenshot

http://www.enlivex.com

Enlivex Therapeutics Ltd. Company Intro

Enlivex Therapeutics Ltd., a clinical stage immunotherapy company, engages in developing allogeneic drugs for immune system rebalancing. Its product candidate is Allocetra, an immunotherapy candidate for the prevention of complications post bone marrow transplantations; treatment of patients that do not respond to steroid treatment upon occurrence of graft vs host disease post bone marrow transplantations; and prevention of cytokine storms, organ damage, and multiple organ failure in sepsis patients. The company also intends to develop its cell-based therapy to be combined with treatments of solid tumors via immune checkpoint rebalancing to enhance the efficacy of various anti-cancer therapies, including chimeric antigen receptor T-Cell therapy and therapies targeting T-Cell receptor therapy. Enlivex Therapeutics Ltd. was founded in 2005 and is headquartered in Nes Ziona, Israel.

Industry

Healthcare

Enlivex Therapeutics Ltd. Headquaters

14 Einstein Street
Nes Ziona,7403618
Israel


Enlivex Therapeutics Ltd. Share price

14 Sep 2022 09:08 GMT

$5.16

-0.11 (-2.09 %)


Enlivex Therapeutics Ltd. Market cap

$92.936 M


WMC RANKING

2022

Enlivex Therapeutics Ltd. # 477

Biotechnology

Latest Enlivex Therapeutics Ltd. News

News 06 Dec 2022

What's Next For Cell Therapy In Oncology? Enlivex (NASDAQ ...

Enlivex (NASDAQ: ENLV) Says It Has The Answers. EQS Group. Published about 12 hours ago. EQS-News: Enlivex Therapeutics, Ltd...

News 06 Dec 2022

What's Next For Cell Therapy In Oncology? Enlivex (NASDAQ ...

Enlivex (NASDAQ: ENLV) Says It Has The Answers. EQS Group. Published about 12 hours ago. EQS-News: Enlivex Therapeutics, Ltd...

News 02 Dec 2022

First Patients Dosed in Phase I/II Trial of Enlivex's Off-the-Shelf ...

Israel --News Direct-- Enlivex Therapeutics, Ltd. On November 13, Enlivex (NASDAQ: ENLV) announced that the first patient has been dosed in its Phase I/II...


WMC Market Score


WMC Market to Revenue Score


Enlivex Therapeutics Ltd. Market Financials


Revenue, Expenses, Profit


Company Currency Revenue Expense Profit Market Cap WMC Sector Score
Enlivex Therapeutics Ltd. USD $0 $11,691 $-14,230 $929M 477
Regeneron Pharmaceuticals, Inc. USD $9,197,600 $3,997,800 $4,003,800 $754,300B 1
Vertex Pharmaceuticals Incorporated USD $6,414,881 $2,617,257 $2,762,032 $713,610B 2
Alexion Pharmaceuticals, Inc. USD $6,261,601 $2,747,200 $681,800 $ 3
Incyte Corporation USD $2,702,913 $2,048,306 $478,480 $150,520B 4

Market Analytics


Company Search vs Top 4 Industry Competitors



Total Enlivex Therapeutics Ltd. Social Followers vs Top 4 Industry Competitors



Enlivex Therapeutics Ltd. Post vs Top 4 Industry Competitors




Enlivex Therapeutics Ltd. Digital Footprint By Size vs Top 4 Industry Competitors



Enlivex Therapeutics Ltd. Digital Footprint By Change Rate vs Top 4 Industry Competitors



Enlivex Therapeutics Ltd. WMC Market Score Calculations


Details Revenue Total Social Followers Total Social Posts Search Volume Digital Footprint Size Digital change (New Pages) WMC Market Score
Enlivex Therapeutics Ltd. 0 0 0 0 0 0 0
Regeneron Pharmaceuticals, Inc. 100 25.50 16.15 22 0 0 28.52
Vertex Pharmaceuticals Incorporated 69.75 35.68 8.95 33 0 0 34.78
Alexion Pharmaceuticals, Inc. 68.08 100 100 22 0 0 100
Incyte Corporation 29.39 5.03 0.04 100 0 0 47.37

Book a demo

Book a free one-on-one demo with one of our team and see exactly how the WMC business intelligence platform can help you protect and grow revenue.

* required fields


You'll learn how to:

  • 1. Automatically monitor your entire digital landscape including competitors
  • 2. View all new industry activity in real time
  • 3. Monitor your position in your industry
  • 4. Enrich your reports and strategy
  • 5. Empower your teams with knowledge

Our platform is loved & trusted by avariety
of world-leading brands

  • unilever
  • wavesight
  • acca
  • abeerdeen
  • UK2
  • umbo
  • rb
Industries